Shareholder Alert: The Ademi Firm Investigates Whether HilleVax, Inc. Is Obtaining a Fair Price for Its Public Shareholders
HLVXMILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating HilleVax (NASDAQ: HLVX) for possible breaches of fiduciary duty and other violations of law in its transaction with XOMA Royalty Corporation. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. In the transaction, shareholders of HilleVax will receive $1.95 per share in cash plus contingent value right
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of HilleVax, Inc. (NASDAQ: HLVX)
HLVXNEW YORK, Aug. 7, 2025 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The...
HILLEVAX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of HilleVax, Inc. - HLVX
HLVXNEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of HilleVax, Inc. (NasdaqGS: HLVX) to XOMA Royalty Corporation (NasdaqGM: XOMA). Under the terms of the proposed transaction, shareholders of HilleVax will receive $1.95 in cash per share, plus one non-transferable contingent value right, representing the right to receive additional payments under cert
HLVX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of HilleVax, Inc. Is Fair to Shareholders
HLVXNEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of HilleVax, Inc. (NASDAQ: HLVX) to XOMA Royalty Corporation is fair to HilleVax shareholders. Under the terms of the proposed transaction, HilleVax stockholders will receive $1.95 in cash per share, plus one non-transferable contingent value right, representing the right to receive additional payments under certain conditions. Halper Sadeh encourages HilleVax shareholders to click here t
HilleVax Q1 EPS $(0.12) Beats $(0.36) Estimate
HLVXHC Wainwright & Co. Reiterates Neutral on HilleVax, Maintains $2 Price Target
HLVXHilleVax Exploring Potential For Continued Development Of Its Norovirus Vaccine Candidates In Adults
HLVXExecutives Buy Around $85M Of 4 Stocks
HLVXAlthough crude oil futures traded higher on Wednesday, there were a few notable insider trades.
HilleVax Announces Initiation Of Phase 2b Clinical Trial Of HIL-214 Vaccine Candidate For The Prevention Of Norovirus-Related Acute Gastroenteritis In Infants
HLVXHilleVax Shares Open For Trade At $18.76; IPO Priced $17/Share
HLVXHilleVax Shares Will Open For Quote At 10:10 a.m. EDT, Expected To Open For Trade After 10:20 a.m. EDT; IPO Priced $17/Share
HLVXHillevax Priced Upsized 11.765M Shares IPO @$17/Share
HLVXPreview: Hillevax, Inc Set To IPO Tomorrow
HLVXHilleVax, Inc (NASDAQ:HLVX) IPO will take place April, 29 on the NASDAQ exchange under the ticker HLVX.
The company is offering shares at an expected price between $16.00 and $18.00 per share with an insider lock-up period of 180 days ending on October 26, 2022.
